https://www.aigom.it/wp-content/uploads/2026/05/Screenshot-2026-05-05-104358.png400311Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-05-05 08:28:522026-05-05 08:49:21PEMBROLIZUMAB OR PLACEBO WITH CHEMORADIOTHERAPY FOLLOWED BY PEMBROLIZUMAB OR PLACEBO FOR NEWLY DIAGNOSED, HIGH-RISK, LOCALLY ADVANCED CERVICAL CANCER (ENGOT-cx11/GOT-3047/KEYNOTE-A18): A RANDOMISED, DOUBLE-BLIND, PHASE 3 CLINICAL TRIAL.
https://www.aigom.it/wp-content/uploads/2026/04/Screenshot-2026-04-21-104313.png448400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-04-21 08:45:252026-05-05 08:59:07ADJUVANT RIBOCICLIB PLUS NONSTEROIDAL AROMATASE INHIBITOR THERAPY IN PATIENTS WITH HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER: 5-YEAR FOLLOW-UP OF NATALEE EFFICACY OUTCOMES AND UPDATED OVERALL SURVIVAL.
https://www.aigom.it/wp-content/uploads/2026/04/ARTAPRILE.png458400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-04-13 16:47:532026-05-05 09:05:28ROMIPLOSTIM VERSUS PLACEBO FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA
https://www.aigom.it/wp-content/uploads/2026/03/ART17.3.png1114700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-03-17 08:26:422026-03-17 08:26:42ADDITION OF CARBOPLATIN TO SEQUENTIAL TAXANE-ANTHRACYCLINE NEOADJUVANT CHEMOTHERAPY IN TRIPLE-NEGATIVE BREAST CANCER: A PHASE III RANDOMIZED CONTROLLED TRIAL.
https://www.aigom.it/wp-content/uploads/2026/03/art10.3.png1079700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-03-10 08:22:402026-03-10 08:22:40TEN-YEAR SURVIVAL AFTER POSTMASTECTOMY CHEST-WALL IRRADIATION IN BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2026/03/ART3.3.png1126700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-03-03 09:12:222026-03-03 09:12:22ADDRESSING COMMON MEDICATIONS THAT INFLUENCE IMMUNOTHERAPY RESPONSE IN SOLID TUMORS.
https://www.aigom.it/wp-content/uploads/2026/02/ART24.2.png1059700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-02-24 07:47:032026-02-24 07:47:03PALBOCICLIB FOR HORMONE-RECEPTOR POSITIVE, HER2-POSITIVE ADVANCED BREAST CANCER.
https://www.aigom.it/wp-content/uploads/2026/02/ART17.2.png1030700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-02-17 09:13:392026-02-17 09:13:39TRASTUZUMAB DERUXTECAN PLUS PERTUZUMAB FOR HER2-POSITIVE METASTATIC BREAST CANCER
https://www.aigom.it/wp-content/uploads/2026/02/ART10.2-1.png1154700Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2026-02-10 08:09:292026-02-10 08:14:33IMMUNE CHECKPOINT INHIBITORS FOR MISMATCH REPAIR-DEFICIENT GASTROESOPHAGEAL ADENOCARCINOMA: OUTCOMES AND FEASIBILITY OF NONOPERATIVE MANAGEMENT AT MAYO CLINIC.
